Two trials recently reported in the New England Journal of Medicine report that use of mammalian target of rapamycin inhibitors does little to halt the progression of autosomal dominant polycystic kidney disease. Do these therapies still have a future in the treatment of this disease?
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Extracellular vesicles and exosomes generated from cystic renal epithelial cells promote cyst growth in autosomal dominant polycystic kidney disease
Nature Communications Open Access 27 July 2021
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ecder, T. et al. in Diseases of the Kidney and Urinary Tract (ed. Schrier, R. W.) 502–539 (Lippincott Williams & Wilkins, Philadelphia, 2007).
Torres, V. E., Harris, P. C. & Pirson, Y. Autosomal dominant polycystic kidney disease. Lancet 369, 1287–1301 (2007).
Grantham, J. J. Mechanisms of progression in autosomal dominant polycystic kidney disease. Kidney Int. Suppl. 63, S93–S97 (1997).
Shillingford, J. M. et al. The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc. Natl Acad. Sci. USA 103, 5466–5471 (2006).
Wu, M. et al. Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press. Res. 30, 253–259 (2007).
Qian, Q. et al. Sirolimus reduces polycystic liver volume in ADPKD patients. J. Am. Soc. Nephrol. 19, 631–638 (2008).
Walz, G. et al. Everolimus in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 830–840 (2010).
Serra, A. L. et al. Sirolimus and kidney growth in autosomal dominant polycystic kidney disease. N. Engl. J. Med. 363, 820–829 (2010).
Perico, N. et al. Sirolimus therapy to halt the progression of ADPKD. J. Am. Soc. Nephrol. 21, 1031–1040 (2010).
Antiga, L. et al. Computed tomography evaluation of autosomal dominant polycystic kidney disease progression: a progress report. Clin. J. Am. Soc. Nephrol. 1, 754–760 (2006).
Acknowledgements
N. Perico and G. Remuzzi are both authors on reference 9; G. Remuzzi is also an author on reference 10.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Perico, N., Remuzzi, G. Do mTOR inhibitors still have a future in ADPKD?. Nat Rev Nephrol 6, 696–698 (2010). https://doi.org/10.1038/nrneph.2010.153
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2010.153
This article is cited by
-
Extracellular vesicles and exosomes generated from cystic renal epithelial cells promote cyst growth in autosomal dominant polycystic kidney disease
Nature Communications (2021)
-
Polycystin-1 but not polycystin-2 deficiency causes upregulation of the mTOR pathway and can be synergistically targeted with rapamycin and metformin
Pflügers Archiv - European Journal of Physiology (2013)
